Using 18F-DOPA PET-CT to Improve Treatment Planning for Recurrent High-Grade Gliomas
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas : a Monocentric Pilot Impact Study on the Practices of Defining Target Volumes Before RAdiotherapy
This study is testing if a special type of scan can help doctors better see and measure brain tumors in patients with recurring high-grade gliomas to improve their treatment plans.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Vandoeuvre les Nancy cedex) |
| Trial ID | NCT04766632 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 18F-DOPA PET-CT scans in accurately delineating tumor volumes for patients with recurrent high-grade gliomas. The research aims to compare the tumor volumes identified by PET-CT with those identified by traditional MRI methods, focusing on improving the planning of re-irradiation treatments. By analyzing the differences in tumor volume delineation, the study seeks to enhance treatment precision and potentially improve patient outcomes. The study will involve adult patients with a confirmed diagnosis of WHO grade III or IV glioma who have experienced a recurrence after standard treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 with a histological diagnosis of WHO grade III or IV glioma who have experienced a local recurrence after standard treatment.
Not a fit: Patients who are undergoing their first treatment or have contraindications to new radiotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate treatment planning and improved survival rates for patients with recurrent high-grade gliomas.
How similar studies have performed: While several studies have explored the use of amino acid PET in glioma treatment planning, this specific approach using 18F-DOPA PET-CT in recurrent cases is novel and has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult \> 18 and \< 75 years old * Status WHO ≤ 2 * Histological diagnosis of WHO grade III or IV glioma, in local recurrence after radiochemotherapy (60Gy/30 sessions + concomitant TEMOZOLOMIDE), postoperatively or exclusively. * Recurrence in the field of initial radiotherapy * Indication for stereotactic radiotherapy alone, validated in neuro-oncology CPR. * Patient affiliated to a social security system * Patient able to give consent Exclusion Criteria: * Contraindication to new radiotherapy * First treatment other than standard radiochemotherapy (60Gy/30 session + concomitant TEMOZOLOMIDE), postoperative or exclusive. * Contraindication to MRI and/or gadolinium injection * Pregnancy, breastfeeding * Follow-up of the patient impossible * Persons deprived of liberty or under guardianship
Where this trial is running
Vandoeuvre les Nancy cedex
- CHRU NANCY Brabois, nuclear medicine department — Vandoeuvre les Nancy cedex, France (Recruiting)
Study contacts
- Principal investigator: Antoine VERGER, MD, PhD — CHRU de Nancy
- Study coordinator: Antoine VERGER, MD,PhD
- Email: a.verger@chru-nancy.fr
- Phone: 0383155567
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.